The National Institute of Allergy and Infectious Diseases (NIAID) has awarded mAbDx, Inc., a major Phase I SBIR grant ($599,913 for a 2-year study) to create a rapid Point of Care test with visual plus/minus readout that will not only diagnose Dengue infections early, but also be prognostic for Severe Dengue (Title: Simultaneous Diagnosis of Dengue and Prognosis of Severe Dengue with a Single Point-of-Care Test, NIAID grant number 1R43AI162484-01A1). The test will be a first-in-class Point of Care test for Dengue diagnosis and Severe Dengue prognosis that could change clinical practice. A simple, inexpensive test that provides timely diagnostic and prognostic results even in resource-limited settings would enable dramatic reductions in Dengue morbidity and mortality, while simultaneously reducing health care costs by allowing clinicians to focus resources effectively and efficiently on patients who may need them most.